Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool
Fraia Melchionda, … , Yutaka Tagaya, Crystal L. Mackall
Fraia Melchionda, … , Yutaka Tagaya, Crystal L. Mackall
Published May 2, 2005
Citation Information: J Clin Invest. 2005;115(5):1177-1187. https://doi.org/10.1172/JCI23134.
View: Text | PDF
Article Vaccines

Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool

Abstract

Current models of T cell memory implicate a critical role for IL-7 in the effector-to-memory transition, raising the possibility that IL-7 therapy might enhance vaccine responses. IL-7 has not been studied, to our knowledge, before now for adjuvant activity. We administered recombinant human IL-7 (rhIL-7) to mice during immunization against the male antigen HY and compared these results with those obtained from mice immunized with rhIL-2 and rhIL-15. Administration of rhIL-7 or rhIL-15, but not rhIL-2, increased effector cells directed against these dominant antigens and dramatically enhanced CD8+ effectors to subdominant antigens. The mechanisms by which the cytokines augmented effector pool generation were multifactorial and included rhIL-7–mediated costimulation and rhIL-15–mediated augmentation of the proliferative burst. The contraction phase of the antigen-specific response was exaggerated in cytokine-treated mice; however, CD8+ memory pools in rhIL-7– or rhIL-15–treated groups demonstrated superior long-term survival resulting in quantitative advantages that remained long after the cytokines were discontinued, as demonstrated by improved survival after challenge with an HY-expressing tumor undertaken several weeks after cytokine cessation. These results confirm the adjuvant activity of rhIL-15 and demonstrate that rhIL-7 also serves as a potent vaccine adjuvant that broadens immunity by augmenting responses to subdominant antigens and improving the survival of the CD8+ T cell memory pool.

Authors

Fraia Melchionda, Terry J. Fry, Matthew J. Milliron, Melissa A. McKirdy, Yutaka Tagaya, Crystal L. Mackall

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
T cell populations from cytokine-treated and control mice undergo equiva...
T cell populations from cytokine-treated and control mice undergo equivalent homeostatic expansion. (A and B) LN T cells (3 × 106) harvested on day 120 after therapy with carrier, rhIL-7, or rhIL-15 as described in Figure 1 were adoptively transferred into lymphopenic SCID recipients. At 22 days after transfer, splenocytes (A) and LN cells (B) in SCID mice were enumerated. Significant differences between control SCID mice versus recipients of adoptive transfer from the various groups are shown. There were no significant differences in the degrees of expansion observed using inocula harvested from rhIL-7–, rhIL-15–, or sham-treated mice.